Ein ETF investiert in Marinus Pharmaceuticals, Inc
Dir gefallen die Informationen zu Marinus Pharmaceuticals Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Marinus Pharmaceuticals Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Marinus Pharmaceuticals Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Marinus Pharmaceuticals Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
21 News & Informationen zur Marinus Pharmaceuticals Inc Aktie
Marinus Pharmaceuticals : to Present at Multiple Upcoming Investor Conferences
Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that members of its leadership team will… | August 25, 2021
Marinus Pharmaceuticals To Present At Multiple Upcoming Investor Conferences
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders,
Scion Asset Management, LLC Buys Discovery Inc, Ovintiv Inc, The GEO Group Inc, Sells Ingles Markets Inc, Zymeworks Inc, Lumen Technologies Inc
GuruFocus Article or News written by insider and the topic is about:
EDGAR Filing Documents for 0001104659-21-107015
Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results In Tuberous Sclerosis Complex And Receives FDA Orphan Drug Designation
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders,
Marinus Pharmaceuticals, Inc. 2021 Q2 – Results – Earnings Call Presentation (NASDAQ:MRNS)
The following slide deck was published by Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q2 2021 Results – Earnings Call Transcript
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2021 Results Conference Call August 10, 2021 8:30 AM ET Company Participants Scott Braunstein – Chief Executive Officer Sasha Damouni – Vice…
Marinus Pharmaceuticals EPS beats by $0.04, misses on revenue (NASDAQ:MRNS)
Marinus Pharmaceuticals (MRNS): Q2 GAAP EPS of -$0.65 beats by $0.04.Revenue of $1.91M misses by $0.7M.Press ReleaseCEO comment: “We are also pleased to report that the FDA indicated…
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnin…
Marinus Pharmaceuticals : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new… | August 6, 2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Nachricht | finanzen.net
Marinus Pharmaceuticals To Provide Business Update And Announce Second Quarter 2021 Financial Results On August 10, 2021
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders,
Marinus Pharmaceuticals Announces Exclusive Collaboration With Orion Corporation For European Commercialization Of Ganaxolone
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders,
Orion Corporation signs European wide marketing and distribution agreement with Marinus Pharmaceuticals for ganaxolone
ORION CORPORATION PRESS RELEASE 3 AUGUST 2021 at 2:00 p.m. EEST Orion Corporation signs European wide marketing and distribution…
Were Hedge Funds Right About Marinus Pharmaceuticals Inc (MRNS)?
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending,…
Hedge Funds Have Never Been This Bullish On Titan International Inc (TWI)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders,
Should I Buy Evelo Biosciences, Inc. (EVLO)?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors…
Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Nachricht | finanzen.net
Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the 'Company” or 'Marinus”), a pharmaceutical company dedicated to the development of innovative …
Stock Alert: Marinus Pharmaceuticals Climbs 11%
Shares of Marinus Pharmaceuticals, Inc. (MRNS) are climbing more than 11% Wednesday morning after the company received a positive response from the FDA that the efficacy and safety data resulting from the company's phase III study on the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD) appear sufficient to support the filing of a New Drug Application (NDA).